Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733689 · ClinicalTrials.gov registry record · Phase 1
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
A Phase 1 study of Gastroesophageal Adenocarcinoma, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05733689 is a Phase 1 study of Gastroesophageal Adenocarcinoma that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 20 participants, below the 148-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05733689, a Phase 1 study of Gastroesophageal Adenocarcinoma, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).
Conditions Studied
Interventions
- COMBINATION_PRODUCT FLOT
- COMBINATION_PRODUCT FOLFOX
- COMBINATION_PRODUCT FOLFIRI
- COMBINATION_PRODUCT FOLFIRINOX
- COMBINATION_PRODUCT PACLITAXEL with or without CARBOPLATIN
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05733689
The ClinicalTrials.gov registry entry for NCT05733689 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (86% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastroesophageal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which FLOT is the first listed.
NCT05733689 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05733689 about?
NCT05733689 is a clinical study titled "Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)". This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).
What is the current status of trial NCT05733689?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-27. Estimated completion is 2027-06.
What conditions does trial NCT05733689 study?
This clinical trial studies the following conditions: Gastroesophageal Adenocarcinoma.
What interventions are being tested in trial NCT05733689?
The interventions under investigation include: FLOT (COMBINATION_PRODUCT), FOLFOX (COMBINATION_PRODUCT), FOLFIRI (COMBINATION_PRODUCT), FOLFIRINOX (COMBINATION_PRODUCT), PACLITAXEL with or without CARBOPLATIN (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05733689?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733689 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RECRUITING · Phase 1
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
-
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
ACTIVE NOT RECRUITING · Phase 1
-
A Study of a Personalized Neoantigen Cancer Vaccine
COMPLETED · Phase 1
-
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.